Document Detail


Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease.
MedLine Citation:
PMID:  19834803     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Intravenous iron has been suggested as a safe and effective treatment of anemia complicating inflammatory bowel disease (IBD). Low molecular weight (LMW) iron dextran has the ability to administer the patient's total iron requirement in a single infusion. AIMS: The aim of this study was to assess the safety and efficacy of the total dose of LMW iron dextran infusion for the treatment of iron deficiency in IBD. METHODS: Fifty IBD patients (27 female, 35 Crohn's disease, 15 ulcerative colitis) were included in the study. Mean +/- standard deviation (SD) hemoglobin and ferritin levels before the infusion were 9.88 +/- 1.42 g/dl and 13.9 +/- 10.9 ng/ml, respectively. A 25-mg test dose was followed by infusion of the total dose of LMW iron dextran based on the iron deficit. Several clinical and laboratory parameters were measured before and on week 4 after infusion. RESULTS: Four patients (8%) developed adverse reactions during the test infusion and did not receive the total-dose infusion. Only one patient developed an allergic reaction during the total-dose infusion. In the remaining 45 patients, the mean +/- SD iron dose that was given was 1,075 +/- 269 mg. The mean +/- SD elevation of hematocrit and hemoglobin on week 4 was 4.9 +/- 1.9% and 1.7 +/- 0.8 g/dl, respectively. Hematopoietic response was observed in 23 of 45 patients (51.1%). CONCLUSION: Total parenteral iron replacement with LMW iron dextran is an easy, safe, and effective alternative method for treating iron deficiency anemia in IBD. Harmless adverse reactions may develop in a minority of patients.
Authors:
Ioannis E Koutroubakis; Pantelis Oustamanolakis; Christos Karakoidas; Gerassimos J Mantzaris; Elias A Kouroumalis
Related Documents :
990053 - Systemic methotrexate toxicity. a pharmacological study of its occurrence after intrath...
2750823 - Anal submucosal injection: a new route for drug administration in pelvic malignancies. ...
18605233 - Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2009-10-16
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  55     ISSN:  1573-2568     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-06-29     Completed Date:  2010-07-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2327-31     Citation Subset:  AIM; IM    
Affiliation:
Department of Gastroenterology, University Hospital Heraklion, Heraklion, Crete, Greece. ikoutroub@med.uoc.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anemia, Iron-Deficiency / drug therapy*,  etiology
Colitis, Ulcerative / complications*
Crohn Disease / complications*
Dose-Response Relationship, Drug
Female
Hematinics / therapeutic use
Humans
Iron-Dextran Complex / administration & dosage,  adverse effects*,  therapeutic use*
Male
Middle Aged
Young Adult
Chemical
Reg. No./Substance:
0/Hematinics; 9004-66-4/Iron-Dextran Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness of the Wraparound Process for Children with Emotional and Behavioral Disorders: A Meta...
Next Document:  Circulating Cytokines Reflect Mucosal Inflammatory Status in Patients with Crohn's Disease.